Section Arrow
CRBU.NASDAQ
- Caribou Biosciences
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Pre Market
Last
 2.06
+0.01 (+0.49%)
Bid
2.06
Ask
2.09
High 2.09 
Low 2.05 
Volume 1792 
Regular Hours
Last
 2.05
+0.22 (+12.02%)
Day High 
2.13 
Prev. Close
1.83 
1-M High
1.925 
Volume 
2.98M 
Bid
2.06
Ask
2.09
Day Low
1.835 
Open
1.87 
1-M Low
1.12 
Market Cap 
170.20M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.65 
20-SMA 1.49 
50-SMA 1.21 
52-W High 2.9995 
52-W Low 0.66 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.62/-0.93
Enterprise Value
195.26M
Balance Sheet
Book Value Per Share
2.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.99M
Operating Revenue Per Share
0.37
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.04 -0.24 -10.53%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.075 -1 -7.10%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0473 -0.0004 -0.84%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.19 +0.35 +5.99%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.1 +0.18 +3.04%
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPRplatform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipelineof allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.